This year's Alzheimer's conference, CTAD, has been particularly exhilarating to Kariya Pharma's Chief Science Officer Christian Hölscher.
The conference included a milestone within one of the areas he has been most occupied with, that is, the effect of GLP-1 analogs on Alzheimer's disease. Specifically, it provided some results coming from the so-called ELAD study, which tested Novo Nordisk's analog liraglutide as a treatment for Alzheimer's.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.